Precision medicine approaches for the management of Ewing sarcoma: current perspectives

References

• FletcherCDMBridgeJAHogendoornPMertensFWHO Classification of Tumours of Soft Tissue and BoneLyonIARC Press2013
   Google Scholar
• SiegelRLMillerKDJemalAStatisticsCCancer statistics, 2018CA Cancer J Clin201868173029313949
   PubMed Web of Science ®Google Scholar
• SubbiahVProspects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderlyCurr Oncol Rep201416940125030655
   PubMed Web of Science ®Google Scholar
• BrohlASSolomonDAChangWThe genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutationPLoS Genet2014107e100447525010205
   PubMed Web of Science ®Google Scholar
• CromptonBDStewartCTaylor-WeinerAThe genomic landscape of pediatric Ewing sarcomaCancer Discov20144111326134125186949
   PubMed Web of Science ®Google Scholar
• TirodeFSurdezDMaXGenomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutationsCancer Discov20144111342135325223734
   PubMed Web of Science ®Google Scholar
• DelattreOZucmanJMelotTThe Ewing family of tumors – a subgroup of small-round-cell tumors defined by specific chimeric transcriptsN Engl J Med199433152942998022439
   PubMed Web of Science ®Google Scholar
• ShernJFChenLChmieleckiJComprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumorsCancer Discov20144221623124436047
   PubMed Web of Science ®Google Scholar
• SandLGSzuhaiKHogendoornPCSequencing overview of Ewing sarcoma: a journey across genomic, epigenomic and transcriptomic landscapesInt J Mol Sci2015167161761621526193259
   PubMed Web of Science ®Google Scholar
• KovarHBlocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapyExpert Opin Ther Targets201418111315132825162919
   PubMed Web of Science ®Google Scholar
• BallingerMLGoodeDLRay-CoquardIMonogenic and poly-genic determinants of sarcoma risk: an international genetic studyLancet Oncol20161791261127127498913
   PubMed Web of Science ®Google Scholar
• BrohlASPatidarRTurnerCEFrequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcomaGenet Med201719895595828125078
   PubMed Web of Science ®Google Scholar
• ZhangJWalshMFWuGGermline mutations in predisposition genes in pediatric cancerN Engl J Med2015373242336234626580448
   PubMed Web of Science ®Google Scholar
• LeeJMLedermannJAKohnECPARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesAnn Oncol2014251324024225019
   PubMed Web of Science ®Google Scholar
• DelattreOZucmanJPlougastelBGene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumoursNature199235963911621651522903
   PubMed Web of Science ®Google Scholar
• SankarSLessnickSLPromiscuous partnerships in Ewing’s sarcomaCancer Genet2011204735136521872822
   PubMed Web of Science ®Google Scholar
• Kawamura-SaitoMYamazakiYKanekoKFusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocationHum Mol Genet200615132125213716717057
   PubMed Web of Science ®Google Scholar
• SolomonDABrohlASKhanJMiettinenMClinicopathologic features of a second patient with Ewing-like sarcoma harboring CIC– FOXO4 gene fusionAm J Surg Pathol201438121724172525321332
   PubMed Web of Science ®Google Scholar
• PierronGTirodeFLucchesiCA new subtype of bone sarcoma defined by BCOR–CCNB3 gene fusionNat Genet201244446146622387997
   PubMed Web of Science ®Google Scholar
• Kousar JahanSKMayannaMKavithaBLPatilAKumariPJahanSKA rare case of translocation (12;22) (p13;Q) in Ewing’s sarcomaIndian J Med Paediatr Oncol2014351899225006293
   PubMedGoogle Scholar
• ShuklaNEwing sarcoma: a tough road to clinically relevant biomarkersPediatr Blood Cancer201562574174225586427
   PubMed Web of Science ®Google Scholar
• ArnaldezFIHelmanLJNew strategies in Ewing sarcoma: lost in translation?Clin Cancer Res201420123050305624756371
   PubMed Web of Science ®Google Scholar
• CotterillSJAhrensSPaulussenMPrognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study GroupJ Clin Oncol200018173108311410963639
   PubMed Web of Science ®Google Scholar
• OberlinODeleyMCBuiBNPrognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)Br J Cancer200185111646165411742482
   PubMed Web of Science ®Google Scholar
• OwenLAKowalewskiAALessnickSLEWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcomaPLoS One200834e196518414662
   PubMed Web of Science ®Google Scholar
• NickersonTChangFLorimerDSmeekensSPSawyersCLPollakMIn vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR)Cancer Res200161166276628011507082
   PubMed Web of Science ®Google Scholar
• CullenKJYeeDSlyWSInsulin-like growth factor receptor expression and function in human breast cancerCancer Res199050148532152773
   PubMed Web of Science ®Google Scholar
• GoochJLvan den BergCLYeeDInsulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death – proliferative and anti-apoptotic effectsBreast Cancer Res Treat199956111010517338
   PubMed Web of Science ®Google Scholar
• HassanABMacaulayVMThe insulin-like growth factor system as a therapeutic target in colorectal cancerAnn Oncol200213334935611996463
   PubMed Web of Science ®Google Scholar
• OlmosDPostel-VinaySMolifeLRSafety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a Phase 1 expansion cohort studyLancet Oncol201011212913520036194
   PubMed Web of Science ®Google Scholar
• TolcherAWRothenbergMLRodonJA Phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumorsJ Clin Oncol20072518 Suppl3002
   Google Scholar
• KurzrockRPatnaikAAisnerJA Phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsClin Cancer Res20101682458246520371689
   PubMed Web of Science ®Google Scholar
• van MaldegemAMBovéeJVPeterseEFHogendoornPCGelderblomHEwing sarcoma: the clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathwayEur J Cancer20165317118026765686
   PubMed Web of Science ®Google Scholar
• MalempatiSWeigelBIngleAMPhase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology GroupJ Clin Oncol201230325626222184397
   PubMed Web of Science ®Google Scholar
• TapWDDemetriGBarnettePPhase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsJ Clin Oncol201230151849185622508822
   PubMed Web of Science ®Google Scholar
• SchwartzGKTapWDQinLXCixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, Phase 2 trialLancet Oncol201314437138223477833
   PubMed Web of Science ®Google Scholar
• WagnerLMFouladiMAhmedAPhase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology GroupPediatr Blood Cancer201562344044425446280
   PubMed Web of Science ®Google Scholar
• GarnettMJEdelmanEJHeidornSJSystematic identification of genomic markers of drug sensitivity in cancer cellsNature2012483739157057522460902
   PubMed Web of Science ®Google Scholar
• StewartEGoshornRBradleyCTargeting the DNA repair pathway in Ewing sarcomaCell Rep20149382984025437539
   PubMed Web of Science ®Google Scholar
• ChoyEButrynskiJEHarmonDCPhase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapyBMC Cancer201414181325374341
   PubMed Web of Science ®Google Scholar
• SankarSBellRStephensBMechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcomaOncogene201332425089510023178492
   PubMed Web of Science ®Google Scholar
• SankarSTheisenERBearssJReversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growthClin Cancer Res201420174584459724963049
   PubMed Web of Science ®Google Scholar
• TawbiHABurgessMBolejackVPembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, Phase 2 trialLancet Oncol201718111493150128988646
   PubMed Web of Science ®Google Scholar
• SpurnyCKailayangiriSJamitzkySProgrammed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomasPediatr Blood Cancer2018651e26719
   Web of Science ®Google Scholar
• RossigCCellular immunotherapy strategies for Ewing sarcomaImmunotherapy20146561162124896629
   PubMed Web of Science ®Google Scholar
• GhisoliMBarveMMennelRThree-year follow up of GMCSF/bi-shRNA (furin) DNA-transfected autologous tumor immunotherapy (Vigil) in metastatic advanced Ewing’s sarcomaMol Ther20162481478148327109631
   PubMed Web of Science ®Google Scholar
• ThielUSchoberSJEinspielerIEwing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cellsOncoimmunology201765e131223928638739
   PubMed Web of Science ®Google Scholar
• HuangXParkHGreeneJIGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomasPLoS One2015107e013315226173023
   PubMed Web of Science ®Google Scholar
• BahramiAWuJDyerMADelattreOPappoASLoss of STAG2 expression and prognosis in Ewing sarcoma family of tumorsJ Clin Oncol20153315 Suppl10024
   Web of Science ®Google Scholar
• HonokiKStojanovskiEMcEvoyMPrognostic significance ofp16INK4a alteration for Ewing sarcomaCancer200711061351136017661343
   PubMed Web of Science ®Google Scholar
• LermanDMMonumentMJMcIlvaineETumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children’s Oncology GroupPediatr Blood Cancer201562575976525464386
   PubMed Web of Science ®Google Scholar
• FagnouCMichonJPeterMPresence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing’s tumor. Société Française d’Oncologie PédiatriqueJ Clin Oncol1998165170717119586882
   PubMed Web of Science ®Google Scholar
• de AlavaELozanoMDPatiñoASierrasesúmagaLPardo-MindánFJEwing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samplesDiagn Mol Pathol1998731521579836070
   PubMedGoogle Scholar
• WestDCGrierHESwallowMMDemetriGDGranowetterLSklarJDetection of circulating tumor cells in patients with Ewing’s sarcoma and peripheral primitive neuroectodermal tumorJ Clin Oncol19971525835889053480
   PubMed Web of Science ®Google Scholar
• AthaleUHShurtleffSAJenkinsJJUse of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumorJ Pediatr Hematol Oncol20012329910411216714
   PubMed Web of Science ®Google Scholar
• ZoubekALadensteinRWindhagerRPredictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluationInt J Cancer199879156609495359
   PubMed Web of Science ®Google Scholar
• ShulmanDSKlegaKImamovic-TucoADetection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology GroupBr J Cancer2018119561562130131550
   PubMed Web of Science ®Google Scholar
• HayashiMChuDMeyerCFHighly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNACancer2016122193015302327351911
   PubMed Web of Science ®Google Scholar
• ShuklaNNPatelJAMagnanHPlasma DNA-based molecular diagnosis, prognostication, and monitoring of patients with EWSR1 fusion-positive sarcomasJCO Precis Oncol20171111
   Web of Science ®Google Scholar
• KrumbholzMHellbergJSteifBGenomic EWSR1 fusion sequence as highly sensitive and dynamic plasma tumor marker in Ewing sarcomaClin Cancer Res201622174356436527283964
   PubMed Web of Science ®Google Scholar